Evidence map›Paper›PMID 35607802›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Duration of Replication-Competent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Shedding Among Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19).

Do Young Kim, Michael Y Lin, Cheryl Jennings, Haiying Li, Jae Hyung Jung, Nicholas M Moore, Isaac Ghinai, Stephanie R Black, Daniel J Zaccaro, John Brofman and 2 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Do Young KimDepartment of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.ORCID 0000-0002-5581-9473
Michael Y LinDepartment of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.
Cheryl JenningsRush Research Cores, Rush University Medical Center, Chicago, Illinois, USA.
Haiying LiDepartment of Pathology, Rush University Medical Center, Chicago, Illinois, USA.
Jae Hyung JungDepartment of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Nicholas M MooreDepartment of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.
Isaac GhinaiChicago Department of Public Health, Chicago, Illinois, USA.
Stephanie R BlackChicago Department of Public Health, Chicago, Illinois, USA.
Daniel J ZaccaroSocial & Scientific Systems, Inc, a DLH Holdings Corporation, Durham, North Carolina, USA.
John BrofmanRML Specialty Hospital, Chicago, Illinois, USA.
Mary K HaydenDepartment of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, USA.
CDC Prevention Epicenter Program

Funding

NCEZID CDC HHS U54 CK000481NCEZID CDC HHS U54 CK000607
6 · The paper itself

Abstract

backgroundPatterns of shedding replication-competent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in severe or critical COVID-19 are not well characterized. We investigated the duration of replication-competent SARS-CoV-2 shedding in upper and lower airway specimens from patients with severe or critical coronavirus disease 2019 (COVID-19).

methodsWe enrolled patients with active or recent severe or critical COVID-19 who were admitted to a tertiary care hospital intensive care unit (ICU) or long-term acute care hospital (LTACH) because of COVID-19. Respiratory specimens were collected at predefined intervals and tested for SARS-CoV-2 using viral culture and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Clinical and epidemiologic metadata were reviewed.

resultsWe collected 529 respiratory specimens from 78 patients. Replication-competent virus was detected in 4 of 11 (36.3%) immunocompromised patients up to 45 days after symptom onset and in 1 of 67 (1.5%) immunocompetent patients 10 days after symptom onset (P = .001). All culture-positive patients were in the ICU cohort and had persistent or recurrent symptoms of COVID-19. Median time from symptom onset to first specimen collection was 15 days (range, 6-45) for ICU patients and 58.5 days (range, 34-139) for LTACH patients. SARS-CoV-2 RNA was detected in 40 of 50 (80%) ICU patients and 7 of 28 (25%) LTACH patients.

conclusionsImmunocompromise and persistent or recurrent symptoms were associated with shedding of replication-competent SARS-CoV-2, supporting the need for improving respiratory symptoms in addition to time as criteria for discontinuation of transmission-based precautions. Our results suggest that the period of potential infectiousness among immunocompetent patients with severe or critical COVID-19 may be similar to that reported for patients with milder disease.

Indexed as

COVID-19HumansRespiratory SystemRNA, ViralSARS-CoV-2Specimen HandlingVirus SheddingRNA, Viralintensive carelong-term acute care hospitalSARS-CoV-2viral culturevirus shedding

Identifiers

PMID35607802
PMCPMC9213867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.